Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-86 |
Sentence |
denotes |
Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. |
T2 |
87-251 |
Sentence |
denotes |
Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity. |
T3 |
252-397 |
Sentence |
denotes |
Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM. |
T4 |
398-584 |
Sentence |
denotes |
Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells. |
T5 |
585-722 |
Sentence |
denotes |
DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro. |
T6 |
723-825 |
Sentence |
denotes |
Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses. |
T7 |
826-957 |
Sentence |
denotes |
Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit. |
T1 |
0-86 |
Sentence |
denotes |
Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. |
T2 |
87-251 |
Sentence |
denotes |
Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity. |
T3 |
252-397 |
Sentence |
denotes |
Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM. |
T4 |
398-584 |
Sentence |
denotes |
Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells. |
T5 |
585-722 |
Sentence |
denotes |
DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro. |
T6 |
723-825 |
Sentence |
denotes |
Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses. |
T7 |
826-957 |
Sentence |
denotes |
Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit. |